ZymoGenetics Experiences a Biotech Disconnect
This article was originally published in RPM Report
It's logical to think that synthetic thrombin is safer than bovine- or plasma-derived equivalents. But ZymoGenetics is finding out it's not an easy sell, especially to Wall Street.
You may also be interested in...
FDA's Division of Drug Marketing, Advertising and Communications has sent half of this year's citations for misleading advertising in the past month
At the half-year mark, FDA had approved eight novel BLAs – more than in all of 2007.
Agency takes issue with part of the better-than-bovine thrombin boast.